ID   ITPA_HUMAN              Reviewed;         194 AA.
AC   Q9BY32; A2A2N2; A4UIM5; B2BCH7; O14878; Q5JWH4; Q9BYN1; Q9BYX0;
AC   Q9H3H8;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 2.
DT   15-MAR-2017, entry version 156.
DE   RecName: Full=Inosine triphosphate pyrophosphatase {ECO:0000255|HAMAP-Rule:MF_03148};
DE            Short=ITPase {ECO:0000255|HAMAP-Rule:MF_03148};
DE            Short=Inosine triphosphatase {ECO:0000255|HAMAP-Rule:MF_03148};
DE            EC=3.6.1.9 {ECO:0000255|HAMAP-Rule:MF_03148, ECO:0000269|PubMed:17090528};
DE   AltName: Full=Non-canonical purine NTP pyrophosphatase {ECO:0000255|HAMAP-Rule:MF_03148};
DE   AltName: Full=Non-standard purine NTP pyrophosphatase {ECO:0000255|HAMAP-Rule:MF_03148};
DE   AltName: Full=Nucleoside-triphosphate diphosphatase {ECO:0000255|HAMAP-Rule:MF_03148};
DE   AltName: Full=Nucleoside-triphosphate pyrophosphatase {ECO:0000255|HAMAP-Rule:MF_03148};
DE            Short=NTPase {ECO:0000255|HAMAP-Rule:MF_03148};
DE   AltName: Full=Putative oncogene protein hlc14-06-p;
GN   Name=ITPA {ECO:0000255|HAMAP-Rule:MF_03148}; Synonyms=C20orf37;
GN   ORFNames=My049, OK/SW-cl.9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBUNIT, SUBCELLULAR LOCATION,
RP   AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Fetal brain;
RX   PubMed=11278832; DOI=10.1074/jbc.M011084200;
RA   Lin S., McLennan A.G., Ying K., Wang Z., Gu S., Jin H., Wu C., Lu W.,
RA   Yuan Y., Tang R., Xie Y., Mao Y.;
RT   "Cloning, expression, and characterization of a human inosine
RT   triphosphate pyrophosphatase encoded by the ITPA gene.";
RL   J. Biol. Chem. 276:18695-18701(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ITPAD
RP   THR-32.
RC   TISSUE=Fetal brain;
RA   Mao Y.M., Xie Y., Zheng Z.H.;
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lung carcinoma;
RA   Fan M.-Z., Chen Z., Cao Z.-M.;
RT   "Molecular cloning of cDNA associated with human lung cancer antigen
RT   and study on its functions.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RA   Danaei Y., Behmanesh M., Sadeghi Zadeh M.;
RL   Submitted (DEC-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon adenocarcinoma;
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-
RT   reactive CTL generated from TIL of colon cancer patients.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung carcinoma, and Neuroblastoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-9; 40-56; 95-110 AND 181-194, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [10]
RP   PROTEIN SEQUENCE OF 10-56 AND 95-130, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [11]
RP   SUBSTRATE SPECIFICITY, FUNCTION, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17090528; DOI=10.1074/jbc.M608708200;
RA   Burgis N.E., Cunningham R.P.;
RT   "Substrate specificity of RdgB protein, a deoxyribonucleoside
RT   triphosphate pyrophosphohydrolase.";
RL   J. Biol. Chem. 282:3531-3538(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   INVOLVEMENT IN EIEE35, AND VARIANT EIEE35 CYS-178.
RX   PubMed=26224535; DOI=10.1002/ana.24496;
RA   Kevelam S.H., Bierau J., Salvarinova R., Agrawal S., Honzik T.,
RA   Visser D., Weiss M.M., Salomons G.S., Abbink T.E., Waisfisz Q.,
RA   van der Knaap M.S.;
RT   "Recessive ITPA mutations cause an early infantile encephalopathy.";
RL   Ann. Neurol. 78:649-658(2015).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.63 ANGSTROMS).
RX   PubMed=17077483; DOI=10.1107/S1744309106041790;
RA   Porta J., Kolar C., Kozmin S.G., Pavlov Y.I., Borgstahl G.E.;
RT   "Structure of the orthorhombic form of human inosine triphosphate
RT   pyrophosphatase.";
RL   Acta Crystallogr. F 62:1076-1081(2006).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.1 ANGSTROMS) ALONE AND IN COMPLEX WITH ITP,
RP   COFACTOR, MAGNESIUM-BINDING SITES, AND SUBSTRATE-BINDING SITES.
RX   PubMed=17138556; DOI=10.1074/jbc.M609838200;
RA   Stenmark P., Kursula P., Flodin S., Graslund S., Landry R.,
RA   Nordlund P., Schueler H.;
RT   "Crystal structure of human inosine triphosphatase. Substrate binding
RT   and implication of the inosine triphosphatase deficiency mutation
RT   P32T.";
RL   J. Biol. Chem. 282:3182-3187(2007).
RN   [16]
RP   VARIANT ITPAD THR-32.
RX   PubMed=12384777; DOI=10.1007/s00439-002-0798-z;
RA   Sumi S., Marinaki A.M., Arenas M., Fairbanks L., Shobowale-Bakre M.,
RA   Rees D.C., Thein S.L., Ansari A., Sanderson J., De Abreu R.A.,
RA   Simmonds H.A., Duley J.A.;
RT   "Genetic basis of inosine triphosphate pyrophosphohydrolase
RT   deficiency.";
RL   Hum. Genet. 111:360-367(2002).
RN   [17]
RP   VARIANT ITPAD THR-32.
RX   PubMed=12436200; DOI=10.1007/s100380200095;
RA   Cao H., Hegele R.A.;
RT   "DNA polymorphisms in ITPA including basis of inosine triphosphatase
RT   deficiency.";
RL   J. Hum. Genet. 47:620-622(2002).
CC   -!- FUNCTION: Pyrophosphatase that hydrolyzes the non-canonical purine
CC       nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate
CC       (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate
CC       (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective
CC       monophosphate derivatives. The enzyme does not distinguish between
CC       the deoxy- and ribose forms. Probably excludes non-canonical
CC       purines from RNA and DNA precursor pools, thus preventing their
CC       incorporation into RNA and DNA and avoiding chromosomal lesions.
CC       {ECO:0000255|HAMAP-Rule:MF_03148, ECO:0000269|PubMed:17090528}.
CC   -!- CATALYTIC ACTIVITY: A nucleoside triphosphate + H(2)O = a
CC       nucleotide + diphosphate. {ECO:0000255|HAMAP-Rule:MF_03148,
CC       ECO:0000269|PubMed:17090528}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:17138556};
CC       Note=Binds 1 Mg(2+) ion per subunit.
CC       {ECO:0000269|PubMed:17138556};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.51 mM for ITP {ECO:0000269|PubMed:11278832,
CC         ECO:0000269|PubMed:17090528};
CC         KM=0.31 mM for dITP {ECO:0000269|PubMed:11278832,
CC         ECO:0000269|PubMed:17090528};
CC         KM=0.57 mM for XTP {ECO:0000269|PubMed:11278832,
CC         ECO:0000269|PubMed:17090528};
CC         KM=40.7 uM for dHAPTP {ECO:0000269|PubMed:11278832,
CC         ECO:0000269|PubMed:17090528};
CC         KM=933 uM for dGTP {ECO:0000269|PubMed:11278832,
CC         ECO:0000269|PubMed:17090528};
CC         Vmax=1520 umol/min/mg enzyme for ITP
CC         {ECO:0000269|PubMed:11278832, ECO:0000269|PubMed:17090528};
CC         Vmax=940 umol/min/mg enzyme for dITP
CC         {ECO:0000269|PubMed:11278832, ECO:0000269|PubMed:17090528};
CC         Vmax=1680 umol/min/mg enzyme for XTP
CC         {ECO:0000269|PubMed:11278832, ECO:0000269|PubMed:17090528};
CC         Note=Vmax values are similar for dITP, dHAPTP and dGTP.;
CC       pH dependence:
CC         Optimum pH is 10. {ECO:0000269|PubMed:11278832,
CC         ECO:0000269|PubMed:17090528};
CC   -!- SUBUNIT: Homodimer. {ECO:0000255|HAMAP-Rule:MF_03148,
CC       ECO:0000269|PubMed:11278832, ECO:0000269|PubMed:17138556}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-2831363, EBI-2831363;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03148,
CC       ECO:0000269|PubMed:11278832}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9BY32-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BY32-2; Sequence=VSP_042548;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9BY32-3; Sequence=VSP_045545;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in heart, liver,
CC       sex glands, thyroid and adrenal gland.
CC   -!- DISEASE: Inosine triphosphate pyrophosphohydrolase deficiency
CC       (ITPAD) [MIM:613850]: A common inherited condition characterized
CC       by the abnormal accumulation of inosine triphosphate in
CC       erythrocytes. It might have pharmacogenomic implications and be
CC       related to increased drug toxicity of purine analog drugs.
CC       {ECO:0000269|PubMed:12384777, ECO:0000269|PubMed:12436200,
CC       ECO:0000269|Ref.2}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry. Three different
CC       human populations have been reported with respect to their ITPase
CC       activity: high, mean (25% of high) and low activity. The variant
CC       Thr-32 is associated with complete loss of enzyme activity, may be
CC       by altering the local secondary structure of the protein.
CC       Heterozygotes for this polymorphism have 22.5% of the control
CC       activity: this is consistent with a dimeric structure of the
CC       enzyme.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 35 (EIEE35)
CC       [MIM:616647]: A form of epileptic encephalopathy, a heterogeneous
CC       group of severe childhood onset epilepsies characterized by
CC       refractory seizures, neurodevelopmental impairment, and poor
CC       prognosis. Development is normal prior to seizure onset, after
CC       which cognitive and motor delays become apparent. EIEE35 is
CC       characterized by onset of seizures in the first months of life
CC       associated with essentially no normal development. Many patients
CC       die in early childhood. {ECO:0000269|PubMed:26224535}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the HAM1 NTPase family. {ECO:0000255|HAMAP-
CC       Rule:MF_03148}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF219116; AAK21848.1; -; mRNA.
DR   EMBL; AF063607; AAG43165.1; -; mRNA.
DR   EMBL; AF026816; AAB82608.2; -; mRNA.
DR   EMBL; EF199841; ABP01354.1; -; mRNA.
DR   EMBL; EF213026; ABO70316.1; -; mRNA.
DR   EMBL; AB062127; BAB93459.1; -; mRNA.
DR   EMBL; AL109976; CAC16798.3; -; Genomic_DNA.
DR   EMBL; AL121891; CAI19399.1; -; Genomic_DNA.
DR   EMBL; AL109976; CAI19399.1; JOINED; Genomic_DNA.
DR   EMBL; AL121891; CAM27676.1; -; Genomic_DNA.
DR   EMBL; AL109976; CAM27676.1; JOINED; Genomic_DNA.
DR   EMBL; AL109976; CAM28311.1; -; Genomic_DNA.
DR   EMBL; AL121891; CAM28311.1; JOINED; Genomic_DNA.
DR   EMBL; CH471133; EAX10541.1; -; Genomic_DNA.
DR   EMBL; BC010138; AAH10138.1; -; mRNA.
DR   EMBL; BI115811; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS13051.1; -. [Q9BY32-1]
DR   CCDS; CCDS46576.1; -. [Q9BY32-2]
DR   CCDS; CCDS58762.1; -. [Q9BY32-3]
DR   RefSeq; NP_001254552.1; NM_001267623.1. [Q9BY32-3]
DR   RefSeq; NP_258412.1; NM_033453.3. [Q9BY32-1]
DR   RefSeq; NP_852470.1; NM_181493.3. [Q9BY32-2]
DR   UniGene; Hs.415299; -.
DR   PDB; 2CAR; X-ray; 1.09 A; A/B=1-194.
DR   PDB; 2I5D; X-ray; 1.63 A; A=1-194.
DR   PDB; 2J4E; X-ray; 2.80 A; A/B/C/D/E/F/G/H=1-194.
DR   PDB; 4F95; X-ray; 2.07 A; A=1-194.
DR   PDBsum; 2CAR; -.
DR   PDBsum; 2I5D; -.
DR   PDBsum; 2J4E; -.
DR   PDBsum; 4F95; -.
DR   ProteinModelPortal; Q9BY32; -.
DR   SMR; Q9BY32; -.
DR   BioGrid; 109909; 53.
DR   IntAct; Q9BY32; 1.
DR   MINT; MINT-5006578; -.
DR   STRING; 9606.ENSP00000369456; -.
DR   DrugBank; DB04272; Citric Acid.
DR   iPTMnet; Q9BY32; -.
DR   PhosphoSitePlus; Q9BY32; -.
DR   BioMuta; ITPA; -.
DR   DMDM; 30173120; -.
DR   EPD; Q9BY32; -.
DR   MaxQB; Q9BY32; -.
DR   PaxDb; Q9BY32; -.
DR   PeptideAtlas; Q9BY32; -.
DR   PRIDE; Q9BY32; -.
DR   TopDownProteomics; Q9BY32-1; -. [Q9BY32-1]
DR   DNASU; 3704; -.
DR   Ensembl; ENST00000380113; ENSP00000369456; ENSG00000125877. [Q9BY32-1]
DR   Ensembl; ENST00000399838; ENSP00000382732; ENSG00000125877. [Q9BY32-3]
DR   Ensembl; ENST00000455664; ENSP00000413282; ENSG00000125877. [Q9BY32-2]
DR   GeneID; 3704; -.
DR   KEGG; hsa:3704; -.
DR   UCSC; uc002wid.4; human. [Q9BY32-1]
DR   CTD; 3704; -.
DR   DisGeNET; 3704; -.
DR   GeneCards; ITPA; -.
DR   HGNC; HGNC:6176; ITPA.
DR   HPA; HPA022824; -.
DR   MalaCards; ITPA; -.
DR   MIM; 147520; gene.
DR   MIM; 613850; phenotype.
DR   MIM; 616647; phenotype.
DR   neXtProt; NX_Q9BY32; -.
DR   OpenTargets; ENSG00000125877; -.
DR   Orphanet; 319684; Inosine triphosphatase deficiency.
DR   Orphanet; 284113; Susceptibility to adverse reaction due to mercaptopurine.
DR   PharmGKB; PA29973; -.
DR   eggNOG; KOG3222; Eukaryota.
DR   eggNOG; COG0127; LUCA.
DR   GeneTree; ENSGT00390000015399; -.
DR   HOGENOM; HOG000293320; -.
DR   HOVERGEN; HBG039521; -.
DR   InParanoid; Q9BY32; -.
DR   KO; K01519; -.
DR   OMA; MKIYFAT; -.
DR   OrthoDB; EOG091G0MUD; -.
DR   PhylomeDB; Q9BY32; -.
DR   TreeFam; TF105614; -.
DR   BRENDA; 3.6.1.19; 2681.
DR   Reactome; R-HSA-15869; Metabolism of nucleotides.
DR   SABIO-RK; Q9BY32; -.
DR   ChiTaRS; ITPA; human.
DR   EvolutionaryTrace; Q9BY32; -.
DR   GeneWiki; ITPA; -.
DR   GenomeRNAi; 3704; -.
DR   PRO; PR:Q9BY32; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000125877; -.
DR   CleanEx; HS_ITPA; -.
DR   ExpressionAtlas; Q9BY32; baseline and differential.
DR   Genevisible; Q9BY32; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0035870; F:dITP diphosphatase activity; EXP:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0036220; F:ITP diphosphatase activity; EXP:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035529; F:NADH pyrophosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047429; F:nucleoside-triphosphate diphosphatase activity; IBA:GO_Central.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0036222; F:XTP diphosphatase activity; EXP:Reactome.
DR   GO; GO:0051276; P:chromosome organization; IEA:Ensembl.
DR   GO; GO:0006193; P:ITP catabolic process; IEA:Ensembl.
DR   GO; GO:0055086; P:nucleobase-containing small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0009143; P:nucleoside triphosphate catabolic process; IBA:GO_Central.
DR   CDD; cd00515; HAM1; 1.
DR   Gene3D; 3.90.950.10; -; 1.
DR   HAMAP; MF_03148; HAM1_NTPase; 1.
DR   InterPro; IPR002637; Ham1p-like.
DR   InterPro; IPR027502; ITPase.
DR   InterPro; IPR029001; ITPase-like_fam.
DR   PANTHER; PTHR11067; PTHR11067; 1.
DR   Pfam; PF01725; Ham1p_like; 1.
DR   SUPFAM; SSF52972; SSF52972; 1.
DR   TIGRFAMs; TIGR00042; TIGR00042; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation; Epilepsy;
KW   Hydrolase; Magnesium; Metal-binding; Nucleotide metabolism;
KW   Nucleotide-binding; Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000255|HAMAP-
FT                                Rule:MF_03148, ECO:0000269|Ref.9}.
FT   CHAIN         2    194       Inosine triphosphate pyrophosphatase.
FT                                /FTId=PRO_0000178280.
FT   REGION       14     19       Substrate binding.
FT   REGION       72     73       Substrate binding.
FT   REGION      149    152       Substrate binding.
FT   REGION      177    178       Substrate binding.
FT   METAL        44     44       Magnesium.
FT   METAL        72     72       Magnesium. {ECO:0000250}.
FT   BINDING      56     56       Substrate.
FT   BINDING     172    172       Substrate.
FT   MOD_RES       2      2       N-acetylalanine. {ECO:0000255|HAMAP-
FT                                Rule:MF_03148, ECO:0000269|Ref.9}.
FT   VAR_SEQ       7     23       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_042548.
FT   VAR_SEQ      23     63       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_045545.
FT   VARIANT      32     32       P -> T (in ITPAD; complete loss of
FT                                enzymatic activity at homozygosity;
FT                                partial loss of activity without ITP
FT                                accumulation in heterozygous individuals;
FT                                dbSNP:rs1127354).
FT                                {ECO:0000269|PubMed:12384777,
FT                                ECO:0000269|PubMed:12436200,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_015576.
FT   VARIANT     178    178       R -> C (in EIEE35; unknown pathological
FT                                significance; dbSNP:rs746930990).
FT                                {ECO:0000269|PubMed:26224535}.
FT                                /FTId=VAR_075084.
FT   CONFLICT     33     33       C -> R (in Ref. 1; AAK21848).
FT                                {ECO:0000305}.
FT   CONFLICT     41     41       D -> G (in Ref. 2; AAG43165).
FT                                {ECO:0000305}.
FT   HELIX         2      5       {ECO:0000244|PDB:2CAR}.
FT   STRAND        9     13       {ECO:0000244|PDB:2CAR}.
FT   HELIX        17     27       {ECO:0000244|PDB:2CAR}.
FT   STRAND       33     38       {ECO:0000244|PDB:2CAR}.
FT   STRAND       45     47       {ECO:0000244|PDB:2J4E}.
FT   HELIX        49     64       {ECO:0000244|PDB:2CAR}.
FT   STRAND       68     77       {ECO:0000244|PDB:2CAR}.
FT   HELIX        78     80       {ECO:0000244|PDB:2CAR}.
FT   HELIX        88    102       {ECO:0000244|PDB:2CAR}.
FT   TURN        103    106       {ECO:0000244|PDB:2CAR}.
FT   STRAND      111    121       {ECO:0000244|PDB:2CAR}.
FT   STRAND      125    127       {ECO:0000244|PDB:2J4E}.
FT   STRAND      130    140       {ECO:0000244|PDB:2CAR}.
FT   HELIX       152    154       {ECO:0000244|PDB:2CAR}.
FT   STRAND      155    157       {ECO:0000244|PDB:2CAR}.
FT   TURN        164    166       {ECO:0000244|PDB:2CAR}.
FT   HELIX       169    175       {ECO:0000244|PDB:2CAR}.
FT   HELIX       177    189       {ECO:0000244|PDB:2CAR}.
SQ   SEQUENCE   194 AA;  21446 MW;  F0EC6A523722DF05 CRC64;
     MAASLVGKKI VFVTGNAKKL EEVVQILGDK FPCTLVAQKI DLPEYQGEPD EISIQKCQEA
     VRQVQGPVLV EDTCLCFNAL GGLPGPYIKW FLEKLKPEGL HQLLAGFEDK SAYALCTFAL
     STGDPSQPVR LFRGRTSGRI VAPRGCQDFG WDPCFQPDGY EQTYAEMPKA EKNAVSHRFR
     ALLELQEYFG SLAA
//
